FIELD: medicine.
SUBSTANCE: present invention refers to biotechnology, more specifically to granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonists, and can be used in medicine. The invention consisting in using the GM-CSF specific antibody in treating or preventing multiple sclerosis in the patients with multiple sclerosis.
EFFECT: invention enables delaying the onset of multiple sclerosis recurrences.
9 cl, 5 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PAIN TREATMENT | 2009 |
|
RU2712166C2 |
| OSTEOARTHRITIS TREATMENT | 2009 |
|
RU2712273C2 |
| PAIN TREATMENT | 2009 |
|
RU2630969C2 |
| LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD FOR MULTIPLE SCLEROSIS TREATMENT | 2013 |
|
RU2639497C2 |
| PEPTIDE | 2014 |
|
RU2675479C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| ANTI-GM-CSF ANTIBODIES AND USING THEM | 2006 |
|
RU2447085C2 |
| METHOD FOR GM-CSFRα INHIBITION IN PATIENT | 2012 |
|
RU2639546C2 |
| METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2012 |
|
RU2670743C9 |
| PEPTIDE | 2014 |
|
RU2667428C2 |
